Gastroenterology
RSSArticles
-
Dapagliflozin Tablets (Farxiga)
A second sodium-glucose cotransporter 2 (sglt2) inhibitor has been approved for the treatment of adults with type 2 diabetes mellitus. These agents increase glucose secretion by inhibiting reabsorption in the kidney. Renal glucose threshold can be lowered to 70-90 mg/dL from a norm of 240 mg/dL in patients with diabetes. Dapagliflozin follows canagliflozin as the second SGLT2 approved and is marketed by Bristol-Myers Squibb and AstraZeneca as Farxiga. -
Effect of Vitamin E and Memantine in Alzheimer's Disease
Among patients with mild-to-moderate Alzheimer's disease, 2000 IU/d of vitamin E resulted in a slower functional decline and a decrease in the caregiver burden. -
Spironolactone for Heart Failure
The authors concluded that in a diverse, community-based population with new systolic heart failure, spironolactone did not reduce death or hospitalization, but did increase the incidence of hyperkalemia. -
Infectious Disease Malpractice: The $1.2 Million Miscommunication
-
Two-step Screening for Ovarian Cancer: A ‘Scissor-step’ Forward?
-
Improving Adherence: Who's Doing the Work?
Approximately 50% of patients with chronic illnesses do not adhere to indicated medications, treatment regimens, and healthy lifestyle changes.
-
Side Effects of Opioids
Constipation is the most commonly reported side effect with opioid therapy. Tolerance does not generally develop. Most patients on chronic opioid therapy require prophylaxis -
Hypertension in the Elderly May Be Associated with Progressive Brain Atrophy
-
Is ‘Silent’ Atrial Fibrillation in Diabetics Associated with Cerebral Neurologic Events?
-
Are Hospitalists Associated with Improvements in Quality of Care?
This study demonstrates an association between the use of hospitalists by a hospital and a reduction in 30-day excess readmission rates for heart failure, acute myocardial infarction, and pneumonia.